Hemophilia Treatment Drugs Market To Report Impressive Growth, Revenue To Surge To US$ 25.61 Billion By 2024

25-Oct-2018 | Zion Market Research

With the presence of a large pool of participants, the global hemophilia treatment drugs market is displaying a highly competitive business landscape, finds a new research report by Zion Market Research (ZMR). Shire Plc, Novo Nordisk A/S, Pfizer, Bayer AG, CSL Limited, and Biogen are some of the key vendors of hemophilia treatment drugs across the world. These players across hemophilia treatment drugs market are focusing aggressively on innovation, as well as on including advanced technologies in their existing products. Over the coming years, they are also expected to take up partnerships and mergers and acquisitions as their key strategy for business development, states the hemophilia treatment drugs market study.

This review is based on a report by Zion Market Research, titled Hemophilia Treatment Drugs Market by Product Type (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents), by Disease Type (Hemophilia A, Hemophilia B, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024.”- Report at https://www.zionmarketresearch.com/report/hemophilia-treatment-drugs-market

Request Sample Request Customization Buy Now

Citing an instance, in September 2018, Bayer AG’s hemophilia A drug therapy for rare kind of genetic disease received accolades and recommendation by European Medicines Agency panel. In yet another instance, in October 2018, Genentech Incorporation – a biotech firm and a subsidiary of Roche Group- declared FDA’s approval of its Hemlibra ® for treating routine prophylaxis for preventing bleeding in adults & children, new born, and elderly people with hemophilia A without factor VIII inhibitors.

Global Hemophilia Treatment Drugs Market

As estimated in this report, the global hemophilia treatment drugs market stood at US$ 17.37 billion in 2017. Witnessing a tremendous rise during the period from 2017 to 2024, the revenue in this hemophilia treatment drugs market is expected to reach US$ 25.61 billion by the end of the forecast period. The main products available in this hemophilia treatment drugs market are recombinant coagulation factor concentrates, plasma derived coagulation factor concentrates, desmopressin, and antifibrinolytic agents. Among them, the demand for recombinant coagulation factor concentrates is relatively higher and the trend is anticipated to remain so over the next few years, notes the research report.

Favorable Government Legislations To Enhance Business Scope

“Extensive need for diagnosis of target population for initiating prophylaxis therapy along with favorable government schemes are predicted to lucratively influence the expansion of hemophilia treatment drugs market in the near future,” says the author of this hemophilia treatment drugs market study. Apart from this, rapid increase in the neo-natal population leading to immense rise in the diagnostic rate is projected to boost hemophilia treatment drugs market trends.

Massive Disease Awareness To Support North America Maintain Dominance

Regionally, North America has been leading the worldwide hemophilia treatment drugs market and is anticipated to continue on the dominant position in the years to come, states the hemophilia treatment drugs market study. Prominent awareness about hemophilia along with introduction of new technologies for treating hemophilia is the key factor behind the dominance of the North America hemophilia treatment drugs market. The high number of market players being headquartered in North America is another significant factor that is supporting this regional hemophilia treatment drugs market.

The global hemophilia treatment drugs market is segmented as follows:

By Product

  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytic Agents

 By Type

  • Hemophilia A
  • Hemophilia B
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com